从医生转型为营销高手的黄安军,带领德镁医药踏上IPO征程。作为康哲药业分拆的皮肤业务平台,德镁医药虽坐拥高毛利率,但三年累计亏损达1.66亿元,主要原因在于高昂的营销支出。数据显示,公司超七成毛利被用于销售及推广。尽管未实现盈利,德镁医药的资金链却相对稳健。得益于控股股东康哲药业的支持,公司三年内获得输血超13亿元,并通过股份转换大幅优化负债结构。此外,2024年最大供应商由康哲药业转变为印度...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.